Gefen Megurim: Where The 2026 Money Is Really Supposed To Come From
Gefen entered 2026 after a 12-month working-capital deficit and negative operating cash flow, so its cash forecast is really a funding test. The projected NIS 95.1 million closing balance relies mainly on a new bond, a Zabotinsky-linked institutional line, and the first Gilboa equity injection, not on self-funded operations.
What This Follow-Up Is Isolating
The main article argued that Gefen entered 2026 with a larger project pipe, but with the bottleneck moving to permits, capital, and timing of recognition. This follow-up isolates only the capital leg: where the 2026 cash is actually supposed to come from, what has already entered the company, what still depends on capital markets and on Zabotinsky, and what remains unresolved at parent level even after the Nati Gilboa deal.
The projected NIS 95.1 million closing balance is not being built by the business itself. Gefen ended 2025 with negative operating cash flow of NIS 17.289 million and with a 12-month working-capital deficit of NIS 3.864 million on a consolidated basis and NIS 4.464 million on a solo basis. The cash forecast was therefore produced because of warning signs, not because the company was entering 2026 from a position of surplus liquidity.
The NIS 20 million institutional line is not generic liquidity. It is tied to the Zabotinsky 20 project in Ashdod, it requires the company to keep meeting the Series A bond covenants, and it can be cut back if a project accompaniment agreement is not signed within nine months.
The Nati Gilboa deal did bring in real cash, but not the whole new equity layer. On March 12, 2026 the company received NIS 14.195 million against 22.18 million shares. The second leg, another NIS 9.716 million, is spread over as much as 36 months, now bears a fixed 7.2% rate, and the meeting materials say the controlling shareholder agreed to provide Gilboa with a loan to finance the purchase of the additional shares.
There is also a constructive side to the picture. Series A is not close to covenant pressure right now: consolidated equity attributable to shareholders of NIS 121.866 million sits far above the NIS 20 million floor, and also above the NIS 25 million threshold that would trigger a 0.25% rate step-up. In addition, the audit committee deferred the Abu-group loan payments until March 2028, subject to quarterly review. That buys time. It does not, by itself, create the cash that 2026 still needs.
The 2026 Bridge, More Capital Markets and Less Business Cash
The right way to read 2026 here is through an all-in cash flexibility lens, not through the income statement. The company’s forecast starts the year with NIS 6.473 million, adds NIS 144.502 million of sources, and ends with a projected closing balance of NIS 95.139 million. But the mix is the real story: the operating line contributes only NIS 3.308 million of expected refunds from government institutions, while the bridge is really built by financing and capital items, NIS 14.2 million from Gilboa, NIS 20 million from the institutional line, NIS 2 million from the bank line, and NIS 80 million from a planned new bond series.
One line that could easily be misread as a wider liquidity source, NIS 20.274 million of "credit received for providing equity to projects with permits and closed bank accompaniment," appears almost word for word again on the uses side as "equity provided at the permit stage." In other words, it is not free cash left at company level. It is a pass-through.
That chart makes the main point clearer than the headline closing balance does. On a simple analytical read, removing only the planned new bond from the bridge cuts the theoretical 2026 closing balance from NIS 95.1 million to NIS 15.1 million. If the institutional line and the bank line do not materialize either, the picture already drops into a deficit of about NIS 6.9 million. Put differently, the year-end cushion depends far less on the business funding itself and far more on Gefen’s ability to keep refinancing through debt markets and credit lines.
| Item | 2026, NIS millions | Status in the filings | What it really means |
|---|---|---|---|
| Government refunds | 3.308 | The only operating source in the forecast | Not recurring business cash, but a specific reimbursement assumption |
| Nati Gilboa deal | 14.2 | Completed on March 12, 2026 | Real cash in, but only the first leg |
| Institutional credit line | 20.0 | Binding agreement exists | Still depends on Zabotinsky reaching bank accompaniment within nine months |
| Bank credit line | 2.0 | Available out of a NIS 4 million framework | A small supplement, not a core funding engine |
| New bond series | 80.0 | Management assumption | The single biggest lever, but not yet closed financing |
Why Zabotinsky Is the Bottleneck for the Institutional Line
The institutional credit report can easily be read on first glance as a generic liquidity boost. That is only partly true. The line is non-revolving until January 25, 2028, it carries prime plus 0.5% to 1.5%, and the principal is due in one payment at final maturity. But the economic anchor of the agreement is one specific project, Zabotinsky 20 in Ashdod. If a project-accompaniment agreement is signed, the company must pledge all project surpluses to the lender. If no accompaniment agreement is signed within nine months, the lender may demand repayment of all or part of the loans or cancel the line.
That is the practical point. This is not NIS 20 million sitting on a shelf regardless of execution. It is a bridge that assumes the company will close accompaniment around one project. So in the 2026 forecast it should not be read as NIS 20 million of general corporate cushion, but as NIS 20 million that still depends on a concrete planning and financing milestone.
The restriction layer matters as well. The company undertook to comply at all times with the financial ratios of Series A. In an event of default it would not be able to make distributions or payments to shareholders or related parties, subject only to narrow exceptions. And by the approval date of the financial statements, the company was already reporting only about NIS 14 million of unused credit capacity. That is a good reminder that the gap between nominal credit lines and true room to maneuver is smaller than the headline numbers suggest.
Gilboa and Abu, Two Helpful Layers That Still Do Not Solve the Problem
In Gilboa’s case, the right distinction is between what has already happened and what is still being framed as future equity. The first leg, NIS 14.195 million, has already come in and is explicitly part of the 2026 forecast. The second leg, 15,181,818 shares for NIS 9.716 million, is spread over 36 months. After the March 2026 amendment it bears a fixed 7.2% charge, and the company makes clear that this obligation is absolute and unconditional. At the same time, the meeting notice says Mr. Abu agreed to provide Gilboa with a loan to finance the purchase of those additional shares, secured by a pledge over the same shares. So the first leg is equity already inside the company, but the rest of the new equity layer is not necessarily clean outside capital that can already be counted as a 2026 cushion.
The same logic applies to the Abu deal, only from the other side of the balance sheet. The company and A.Y.Z.Y Abu 2025 are together supposed to repay roughly NIS 38.9 million to the Abu Group, NIS 20.5 million at A.Y.Z.Y Abu 2025 level and NIS 18.4 million at company level, in eight fixed quarterly principal payments of NIS 5 million each plus interest. The audit committee decided to defer the full payment stream until March 2028, with a quarterly review of whether the financial position allows a return to the original schedule. That matters a great deal for 2026 because the deferral prevents an immediate cash outflow. But it is a deferral, not a deletion of the claim.
This is exactly where company-level cash comes back into the picture. In the separate statements, cash and cash equivalents, including deposits with banks, stood at only NIS 6.413 million at the end of 2025. That is not an empty balance. But it is also not the kind of cushion that allows the market to ignore how much of the 2026 bridge still depends on debt issuance, on credit lines, and on deferred payments to the controlling shareholder. That is why the Series A covenant story and the Abu deferral story are both time-buying mechanisms, not substitutes for parent-level liquidity.
What Has To Happen Now
For Gefen, 2026 looks like a bridge year. For that bridge to hold, three things need to happen almost together.
First, Zabotinsky needs to reach bank accompaniment so that the institutional line stays fully available. Without that, one of the most meaningful funding components in the forecast becomes too conditional.
Second, the new bond series has to move from management assumption to closed financing, and on terms that do not eat into the flexibility that already rests on covenants, interest cost, and refinancing capacity.
Third, the equity that projects need at permit stage has to arrive on time. Otherwise the NIS 20.274 million source line and the NIS 20.274 million use line will keep offsetting each other without leaving a real free cushion behind.
If those three things happen, the Abu-payment deferral and the current Series A covenant headroom really do buy the company time. If one of them slips, the company gets back very quickly to the same place the main article identified, a project pipe that looks stronger than the liquidity supporting it.
The current thesis: the money for 2026 is supposed to come mainly from capital markets, credit lines, and the first Gilboa cash injection, not from ongoing operations. So the key question around Gefen right now is not whether it has projects, but whether those three funding levers actually turn into accessible company-level cash in time.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.